Back
Vertex Pharmaceuticals Quote, Financials, Valuation and Earnings
Buy
63
VRTX
Vertex Pharmaceuticals
Last Price:
294.52
Seasonality Move:
5.65%
7 Day Trial
ALL ACCESS PASS
$
7
Vertex Pharmaceuticals Price Quote
$294.52
Vertex Pharmaceuticals Key Stats
Buy
63
Vertex Pharmaceuticals (VRTX)
is a Buy
Day range:
$292.12 - $295.66
52-week range:
$176.36 - $301.80
Dividend yield:
0%
P/E ratio:
32.69
P/S ratio:
9.11
P/B ratio:
6.33%
Volume:
990.8K
Avg. volume:
1.5M
1-year change:
51.18%
Market cap:
$75.5B
Revenue:
$7.6B
EPS:
$12.37
How Much Does Vertex Pharmaceuticals Make?
-
How Much Are Vertex Pharmaceuticals's Sales Annually?
VRTX Revenues are $7.6B -
How Much Profit Does Vertex Pharmaceuticals's Make A Year?
VRTX net income is $2.3B
Is Vertex Pharmaceuticals Growing As A Company?
-
What Is Vertex Pharmaceuticals's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.22% -
What Is Vertex Pharmaceuticals's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 11.04%
Vertex Pharmaceuticals Stock Price Performance
-
Did Vertex Pharmaceuticals Stock Go Up Last Month?
Vertex Pharmaceuticals share price went up by 1.56% last month -
Did VRTX's Share Price Rise Over The Last Year?
VRTX share price rose by 51.18% over the past 1 year
What Is Vertex Pharmaceuticals 52-Week High & Low?
-
What Is Vertex Pharmaceuticals’s 52-Week High Share Price?
Vertex Pharmaceuticals has traded as high as $301.80 over the past 52 weeks -
What Is Vertex Pharmaceuticals’s 52-Week Low Share Price?
Vertex Pharmaceuticals has traded as low as $176.36 over the past 52 weeks
Vertex Pharmaceuticals Price To Free Cash Flow
-
Is Vertex Pharmaceuticals Stock Overvalued?
Vertex Pharmaceuticals is trading at a price to free cash flow ratio of 20.09 -
Is Vertex Pharmaceuticals Stock Undervalued?
Vertex Pharmaceuticals EV to Free Cash Flow ratio is 17.50 -
What Is Vertex Pharmaceuticals’s Price Earnings Growth Ratio?
VRTX PEG ratio is 0.38 -
Is Vertex Pharmaceuticals Trading At A Premium To Earnings?
Vertex Pharmaceuticals EV to EBIT ratio is 16.60
Is It Risky To Buy Vertex Pharmaceuticals?
-
How Much Debt Does Vertex Pharmaceuticals Have?
Total long term debt quarterly is $0 -
How Much Cash Does Vertex Pharmaceuticals Have?
Cash and short term investments quarterly total is $9.3B -
What Is Vertex Pharmaceuticals’s Book Value Per Share?
Book value per share is 46.61
Is Vertex Pharmaceuticals Cash Flow Positive?
-
What Is VRTX Cash Flow From Operations?
Cash flow from operations (TTM) is $4B -
What Is Vertex Pharmaceuticals’s Cash Flow From Financing?
Cash flow from financing (TTM) is -$1B -
What Is Vertex Pharmaceuticals’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$299.4M
Vertex Pharmaceuticals Return On Invested Capital
-
Is Management Doing A Good Job?
VRTX return on invested capital is 30.92% -
What Is Vertex Pharmaceuticals Return On Assets?
ROA measures how assets are converting to revenues and is 23.45% -
What Is VRTX Return On Equity?
ROE is a measure of profitability and is 30.92%
Vertex Pharmaceuticals Earnings Date & Stock Price
-
What Is Vertex Pharmaceuticals's Stock Price Today?
A single share of VRTX can be purchased today for 294.52 -
What Is Vertex Pharmaceuticals’s Stock Symbol?
Vertex Pharmaceuticals trades on the S&P500 under the ticker symbol: VRTX -
When Is Vertex Pharmaceuticals’s Next Earnings Date?
The next quarterly earnings date for Vertex Pharmaceuticals is scheduled on November 2, 2022 -
When Is VRTX's next ex-dividend date?
Vertex Pharmaceuticals's next ex-dividend date is August 15, 2022 -
How To Buy Vertex Pharmaceuticals Stock?
You can buy Vertex Pharmaceuticals shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Vertex Pharmaceuticals Competitors
-
Who Are Vertex Pharmaceuticals's Competitors?
Below is a list of companies who compete with Vertex Pharmaceuticals or are related in some way:
Vertex Pharmaceuticals Dividend Yield
Data Unavailable
Vertex Pharmaceuticals Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 1103.85% | 2.78% |
| Revenue: | 22.46% | 3.04% |
Analyst Recommendations
| Buy Recommendations: | 11 |
|---|---|
| Hold Recommendations: | 10 |
| Sell Recommendations: | 0 |
| Price Target: | 307.87 |
| Upside from Last Price: | 4.53% |